Related Experiment Video

Updated: May 31, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric

Evgeny A Idelevich1, Christof von Eiff, Alexander W Friedrich

  • 1University Hospital of Münster, Institute of Medical Microbiology, D-48149 Münster, Germany.

Antimicrobial Agents and Chemotherapy
|July 13, 2011
PubMed

Insights

The novel chimeric endolysin PRF-119 shows potent antistaphylococcal activity. It is highly effective against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.

Area of Science:

  • Microbiology
  • Biochemistry
  • Drug Discovery

Background:

  • Staphylococcus aureus infections pose a significant public health threat.
  • The rise of antibiotic resistance necessitates novel therapeutic strategies.
  • Endolysins are phage-derived proteins with antimicrobial properties.

Purpose of the Study:

  • To evaluate the antistaphylococcal activity of the novel chimeric endolysin PRF-119.
  • To determine the Minimum Inhibitory Concentration (MIC) of PRF-119 against various Staphylococcus aureus strains.
  • To assess the specificity of PRF-119 against coagulase-negative staphylococci.

Main Methods:

  • Microdilution method was employed to determine antimicrobial activity.
  • Minimum Inhibitory Concentration (MIC50 and MIC90) values were calculated.
  • Testing was performed on clinical isolates of methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and coagulase-negative staphylococci.

Main Results:

  • PRF-119 demonstrated potent activity against MSSA with MIC50 of 0.098 μg/ml and MIC90 of 0.391 μg/ml.
  • Against MRSA, PRF-119 showed MIC50 and MIC90 values of 0.391 μg/ml.
  • No significant activity was observed against coagulase-negative staphylococci (MIC >50 μg/ml).

Conclusions:

  • PRF-119 exhibits excellent and specific antistaphylococcal activity.
  • The endolysin PRF-119 is a promising candidate for combating S. aureus infections.
  • Further research into PRF-119 as a therapeutic agent is warranted.

More Related Videos

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds06:36

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds

Published on: September 8, 2021

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...